

INTEREST 2022

INTERNATIONAL CONFERENCE ON
HIV TREATMENT, PATHOGENESIS,
AND PREVENTION RESEARCH IN
RESOURCE-LIMITED SETTINGS



KAMPALA, UGANDA
10-13 MAY 2022

#INTEREST2022



Programme Book



AMSTERDAM INSTITUTE FOR
GLOBAL HEALTH & DEVELOPMENT



interestconference.org



Dear colleagues and friends,

We welcome you to the **16th annual INTEREST Conference** for the year 2022. This is the first hybrid INTEREST Conference. To improve access, it will combine in person attendance with virtual presence. The 14th and 15th INTEREST Conferences that were organised during the COVID-19 pandemic have given us the experience and expertise to deliver a world class conference from a digital platform. Though the pandemic has disrupted the economy and health systems of many countries, it has, nonetheless, offered us the opportunity to adapt and demonstrate our resilience as humankind by incorporating innovative strategies to deliver services to those in need. Once again, Kampala, which hosted the 1st INTEREST Conference in 2007, will secure another success as we organise our first hybrid conference in Speke Resort in Munyonyo. The INTEREST Conference has remained an important activity in the scientific calendar in the Africa region and has served as an opportunity for exchange of research and implementation science, ideas, and findings. It has also served as an opportunity for capacity building for our young investigators. Our young investigators remain critical in developing a core of research scientists for the next generation. The INTEREST family is a movement that seeks to advance and share knowledge on HIV/AIDS whilst building capacity and cultivating a community of young investigators. We are pleased to announce that we received 562 abstract submissions from 43 countries this year. Out of this, 420 were accepted for either oral, mini-oral or poster presentations.

The COVID-19 landscape continues to evolve with an increased availability of vaccines today as compared to 12 months ago. Vaccine uptake, unfortunately, remains suboptimal with challenges of vaccine hesitancy, misinformation, and supply chain. Services for persons living with HIV, TB, and malaria have almost been normalized. Differentiated service delivery options to provide client approaches are currently being implemented to mitigate the effect the COVID-19 pandemic. The development and roll out of long-acting agents for prevention and treatment is progressing steadily. Whilst countries make progress towards 95-95-95, INTEREST 2022 will serve as pivot for attaining epidemic control within the context of a pandemic.

With the support of the International Conference Committee, we have developed a scientific programme that provides state of the art presentations on the interaction between HIV and COVID-19, new developments in prevention and treatment technologies, HIV comorbidities, elimination of mother to child transmission, HIV in children, orphans and vulnerable children, and stigma and discrimination, among others.

We look forward to engaging and interactive sessions during the conference. We have also planned grantspersonship sessions for our young investigators covering the requirements of key donor agencies. Our mentoring sessions will continue to advise, encourage, and support our young investigators to reach their full potential. For the first time in the history of the INTEREST Conference, we will award the two highest scoring abstracts in honour of the late Professors Joep Lange and Charles Boucher, the INTEREST co-founders. We hope that this will motivate our young scientists to strive for greatness.

We look forward to having you participate in INTEREST 2022.

Sincerely,

Sabrina Bakeera-Kitaka - Local Co-Chair

Andrew Kambugu - Local Co-Chair

Kwasi Torpey - Scientific Chair

Elly Katabira - Conference Co-Chair



**Sabrina Bakeera-Kitaka,
MBChB, MMed, PhD**

Makerere University College
of Health Sciences /
Mulago National Referral
Hospital, Uganda



**Andrew Kambugu,
MBChB, MMed, FRCP**

Infectious Diseases
Institute, Uganda



**Kwasi Torpey,
MD, PhD, MPH, FGCP,
FWACP**

University of Ghana,
Ghana



**Elly Katabira,
MD, FRCP**

Makerere University College
of Health Sciences, Uganda

General Information

Abstracts

Accepted abstracts are published in Reviews in Antiviral Therapy & Infectious Diseases, Volume 2022_2.

Badge Policy

All registered delegates are provided with a conference badge. Admission to all events is restricted to registered delegates and official guests wearing their name badges. Please wear your badge at all times to ensure admission to the conference sessions. 25 USD will be charged for replacing a lost badge.

Certificate of Attendance

Certificates of attendance will be sent by e-mail in the week following the conference after completion of the post-conference survey.

Conference Secretariat

The conference secretariat is located at the registration desk in the pre-function area of the conference room. It is open throughout the conference to address all your questions concerning logistics.

COVID-19 Measurements

Please always follow the rules and regulations of the host country and the venue.

Face Masks

Attendees are required to wear a face mask in order to enter the conference venue. The face mask must be worn during the entire length of the conference. Wearing a face mask will not be mandatory in the areas that are designated to the consumption of food and beverages.

Hand Sanitizer

Multiple hand sanitizer stations will be set up throughout the conference venue. Please make sure to use them regularly.

Currency

The Ugandan Shilling (UGX) is the currency of Uganda. United States dollars are widely accepted.
1 USD = 3,595.5988 Ugandan Shilling (April 2022).

Early Morning Sessions

On Wednesday May 11, Thursday May 12, and Friday May 13 from 07.00 to 07.50, three parallel early morning sessions will be taking place:

1. The Joep Lange Career Guidance Sessions are hosted by well-published, world-class scientists who explain how they started their research career; give advice on successful grant writing, mentorship, and publication; and answer questions from aspiring junior researchers. Each session is limited to 40 delegates so please sign up at the registration desk to secure your spot.
2. Grantspersonship sessions will see research funders such as Fogarty International Center, U.S. NIH (National Institutes of Health); AFRICAN Forum for Research and Education in Health (AFREhealth) ANRS - Maladies infectieuses émergentes (France Recherche Nord & Sud Sida hépatites), and others discuss opportunities and describe the profiles of successful applications. Each session is limited to 40 delegates so please sign up at the registration desk to secure your spot.
3. Themed poster discussion sessions will be led by members of the International Conference Committee. The authors of 5 or 6 selected abstracts have been chosen to present their posters by topic. Space is not limited as these will take place in the poster display area. The topics covered each morning will be announced the session prior.

Exhibition

Visiting the exhibition stands in the pre-function area will give you the opportunity to meet and network with key suppliers and industry leaders. This will help keep you up-to-date with the latest industry developments.

Feedback

Your feedback is very valuable to us as it allows us to continue to improve future INTEREST Conferences. Please complete the feedback forms that are distributed via email at the end of each conference day. On the last day, the conference organisers will distribute the final feedback form and we ask you to return this form to the hostesses or to the registration desk. You will receive the group photo in return. Your feedback is much appreciated – we will use it to improve the programme in 2023.

Disclaimer: This conference aims to offer delegates the opportunity to share information. The organisers of this conference, AIGHD and Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims that may result from the use of information or publications from this conference.



Group Picture

On Tuesday, May 10, prior to the refreshment break at 15.45, we will take a group picture. Instructions will be provided in the session before the photo shoot. Please follow directions from the conference organisers to make this run as smoothly as possible. You will receive a printed copy of the group photo when you hand in the final evaluation form on Friday, May 13.

Notes - OnAIR

You will be able to take notes in the virtual portal during the conference. Any notes that you take throughout the event can be exported by selecting the Export icon on the top right of the screen near your Profile image.

OnAIR - Virtual Platform

OnAIR is the virtual conference platform being used for INTEREST 2022. A video tutorial on how to use the conference portal can be found via this link www.youtube.com/watch?v=Cp398ZBSJPY.

Posters

Posters are displayed in both the conference room and the SBR garden on the ground floor. Please seek out the posters during refreshment breaks and during the early morning poster discussion sessions. All poster presenters are asked to be at their posters at a specific time so that you can discuss their work with them. Each day, these times and the topics will be announced and you will be able to find them on page 6 and 7 of this programme book.

Presentations and Webcasts

The webcast and PDF presentations are available OnAIR for three weeks after the conference. After this time, they will be made accessible on demand via the conference websites. (www.interestconference.org and www.AcademicMedicalEducation.com)

Social Media



Follow us on Instagram @INTERESTConference and Twitter @INTERESTconf to stay up-to-date on the conference! We encourage you to post news about INTEREST on your social media accounts and tweet about INTEREST as often as you please during the conference. You can either post your own tweet to your followers using the hashtag #INTEREST2022 or retweet a message through the official @INTERESTconf account.

Speakers

Presenters are requested to submit their presentation on a USB stick as early as possible, latest in the break prior to their session. Our technician will be available for you at the technician table.

Time Zones

Times are in East Africa Time (EAT). If you need to convert the times to your timezone, this website can help you: www.worldtimebuddy.com.

WiFi

Free WiFi is available throughout the conference venue. To connect to the WiFi enter the password: **INTEREST2022**



Poster Viewing Sessions

Tuesday Morning Coffee

Basic Science and HIV Cure	All Posters
COVID-19 in Africa	Even Poster Numbers
Antiretroviral Treatment and HIV Care	Even Poster Numbers

Tuesday Afternoon Coffee

COVID-19 in Africa	Odd Poster Numbers
Antiretroviral Treatment and HIV Care	Odd Poster Numbers

Wednesday Morning Coffee

Health System Strengthening	Even Poster Numbers
HIV Prevention and New Technologies (PrEP, Vaccines, Antibodies)	Even Poster Numbers
Implementation Science, Cost-Effectiveness, and Modelling	Even Poster Numbers
Paediatrics and Prevention of Mother-To-Child Transmission (PMTCT)	Even Poster Numbers
Epidemiology	Even Poster Numbers
Community/Civil Society Engagement	Even Poster Numbers

Wednesday Afternoon Coffee

Health System Strengthening	Odd Poster Numbers
HIV Prevention and New Technologies (PrEP, Vaccines, Antibodies)	Odd Poster Numbers
Implementation Science, Cost-Effectiveness, and Modelling	Odd Poster Numbers
Paediatrics and Prevention of Mother-To-Child Transmission (PMTCT)	Odd Poster Numbers
Epidemiology	Odd Poster Numbers
Community/Civil Society Engagement	Odd Poster Numbers



Thursday Morning Coffee

Economics, Innovative Financing, Development Goals	All Poster Numbers
HIV Co-Infections, Including Hepatitis, Tuberculosis, Sexually Transmitted Infections, and (Re)Emerging Pathogens	Even Poster Numbers
Information Technology Innovations for HIV (mHealth, Electronic Records, Social Media, etc.)	Even Poster Numbers
Knowledge Translation to Policy and Programming	Even Poster Numbers
Laboratory Monitoring/Diagnostics	Even Poster Numbers
Socio-Behavioural Research	Even Poster Numbers

Thursday Afternoon Coffee

HIV Co-Infections, Including Hepatitis, Tuberculosis, Sexually Transmitted Infections, and (Re)Emerging Pathogens	Odd Poster Numbers
Information Technology Innovations for HIV (mHealth, Electronic Records, Social Media, etc.)	Odd Poster Numbers
Women and HIV	Even Poster Numbers
Key Populations: Prevention and Treatment Challenges	Even Poster Numbers
Knowledge Translation to Policy and Programming	Odd Poster Numbers
Laboratory Monitoring/Diagnostics	Odd Poster Numbers

Friday Morning Coffee

Women and HIV	Odd Poster Numbers
Key Populations: Prevention and Treatment Challenges	Odd Poster Numbers
Structural Determinants and Interventions	All Posters
Socio-Behavioural Research	Odd Poster Numbers



Amsterdam Institute for Global Health and Development

The Amsterdam Institute for Global Health and Development (AIGHD) is an international research and education institute that works to develop sustainable solutions to major health problems. By taking a problem-oriented approach, AIGHD transcends the boundaries of traditional academic disciplines and integrates three fundamental activities into one institute: research, education, and policy. Founded by the late Professor Joep Lange in 2009, AIGHD brings together experts from multiple disciplines including biomedicine, economics, and social and behavioral sciences to address the most critical medical, social, economic, and political challenges in global health and development.



**academic
medical education**

Virology Education & Academic Medical Education

Under the guidance of the late esteemed virologist Prof. Dr. Charles Boucher, Virology Education and Academic Medical Education have been a driving force in the global medical community with the primary aim to further research and enable knowledge sharing. We specialize in medical programs in the fields of HIV, hepatitis, COVID-19, emerging viruses, NASH, liver disease, pharmacology, and oncology in a variety of learning formats that maintain a balance between educational content and networking. Virology Education and Academic Medical Education are proud to be leading medical educators that supply healthcare professionals with the tools needed to work effectively.



Kwasi Torpey,
MD, PhD, MPH, FGCP, FWACP
University of Ghana,
Ghana



Elly Katabira,
MD, FRCP
Makerere University College of
Health Sciences,
Uganda



Linda-Gail Bekker,
MBChB, DTMH, DCH,
FCP(SA), PhD
Desmond Tutu Health Foundation /
University of Cape Town,
South Africa



Elizabeth Anne Bukusi,
MBChB, MMed (ObGyn),
MPH, PhD, PGD (Research
Ethics), MBE (Bioethics), CIP
Kenya Medical Research Institute,
Kenya




Guido Ferrari,
MD
Duke University Medical Center,
United States



Pierre-Marie Girard,
MD, PhD
Hôpital Saint-Antoine /
Université Pierre et Marie Curie,
France



Catherine Hankins,
MD, PhD, FRCPC, CM
Amsterdam Institute for Global Health
and Development (AIGHD) /
McGill University,
The Netherlands / Canada



Peter Kilmarx,
MD, FACP, FIDSA
John E. Fogarty International Center,
National Institutes of Health,
United States



**Nagalingeswaran
Kumarasamy,**
MD
Voluntary Health Services Hospital,
India



Chew Luo,
MD, PhD
UNICEF, United States /
University Teaching School,
Zambia

International Conference Committee



Timothy Mastro,
MD, FACP, DTM&H

FHI 360 / University of North Carolina at Chapel Hill,
United States



Nyaradzo Mavis Mgodi,
MBChB, MMed

University of Zimbabwe Clinical Trials Research Centre,
Zimbabwe



Jean B. Nachega,
MD, PhD, MPH, FRCP, FAAS

University of Pittsburgh / Johns Hopkins University, United States
Stellenbosch University,
South Africa



Samiratou Ouedraogo,
DPharm, MPH, PhD

University Joseph Ki-Zerbo,
Burkina Faso



Sam Phiri,
DCM, MSc, PhD

Partners in Hope,
Malawi



Anton Pozniak,
MD, FRCP

Chelsea and Westminster Hospital
NHS Foundation Trust / Imperial College of London,
United Kingdom



Anna Laura Ross,
PhD

World Health Organization,
Switzerland



Coumba Touré Kane,
PharmD, PhD

Laboratoire de Bactériologie-Virologie
CHU Le Dantec, Cheikh Anta Diop University,
Senegal



François Venter,
MD, FCP, PhD

Ezintsha, Sub-division of Wits RHI,
University of the Witwatersrand,
South Africa



Stephen Watiti,
MD

The National Forum of People Living with HIV/AIDS Networks in Uganda (NAPHOPANU),
Uganda,



Sabrina Bakeera-Kitaka,

MBChB, MMed, PhD

Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda



Andrew Kambugu,

MBChB, MMed, FRCP

Infectious Diseases Institute, Uganda



Tracy Ahumuza,

B.A.Com


Infectious Diseases Institute, Uganda



Barbara Castelnovo,

MD, PhD

Infectious Diseases Institute, Uganda



Lisa Mills,

MD, MSc

Centers for Disease Control, Uganda



Maria Sarah Nabaggala,

BStat, MSc

Infectious Diseases Institute, Uganda



Lillian Tatweba

Uganda AIDS Commission, Uganda



Stephen Watiti

MD

The National Forum of People Living with HIV/AIDS Networks in Uganda (NAPHOPANU), Uganda

Serge Eholie, MD, PhD,	CHU de Treichville, University of Abidjan, Ivory Coast
Grace John-Stewart, MD, PhD, MPH,	University of Washington, United States
Saidi Kapiga , MD, MPH, ScD,	Mwanza Intervention Trials Unit / National Institute for Medical Research (NIMR) / London School of Hygiene & Tropical Medicine (LSHTM), Tanzania / United Kingdom
Sinata Koulla-Shiro, MD,	Ministry of Health, Cameroon
Richard Koup, MD,	Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), United States
Sabin Nsanzimana, MD, PhD, FRCP,	Rwanda Biomedical Center, Rwanda
Helen Rees, MD, MA, MRCGP,	WITS Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, South Africa
Mauro Schechter, MD, PhD,	Federal University of Rio de Janeiro, Brazil
Robert Schooley, MD,	University of California, United States
Stefano Vella, MD,	Istituto Superiore di Sanità, Italy
Debrework Zewdie, PhD,	City University New York School of Public Health & Health Policy, United States

Our Team



Karin Siebelt
Senior Project
Manager
karin@amededu.com



Marloes Nijboer
Senior Project
Manager
m.nijboer@aighd.org



Magda Sevlidou
Project
Coordinator
magda.sevlidou@amededu.com



Diede Smith
Project
Manager
d.smith@aighd.org



Jacqueline Weiner
Communications
Manager
j.weiner@aighd.org



Programme

Tuesday, 10 May

Times are in East African Time (EAT)

07:30	Registration Desk Open
08:00	Coffee & Tea
Session 1	Opening of the Conference <i>Chair: Kwasi Torpey, Elly Katabira, Sabrina Bakeera-Kitaka, and Andrew Kambugu</i>
09:00	Welcome from the Conference Co-Chairs Kwasi Torpey, MD, PhD, MPH, FGCP, FWACP University of Ghana, Ghana <i>Scientific Chair</i> Elly Katabira, MD, FRCP Makerere University College of Health Sciences, Uganda <i>Conference Co-Chair</i> Sabrina Bakeera-Kitaka, MBChB, MMed, PhD Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda <i>Local Co-Chair</i> Andrew Kambugu, MBChB, MMed, FRCP Infectious Diseases Institute, Uganda <i>Local Co-Chair</i>
09:10	The UPHIA 2020 (Uganda Country Results): Highlights Joshua Musinguzi, MD, MSc Assistant Commissioner, AIDS Control Programme, Ministry of Health, Uganda
09:25	Update on Uganda's Multi-Sectoral Response to HIV/AIDS Nelson Musoba, MD, MPH Director General, Uganda AIDS Commission (UAC), Uganda
09:40	Remarks from UNAIDS Uganda Country Director Jotham Mubangizi Ag. Country Director, UNAIDS, Uganda
09:50	Community perspective - COVID-19 Impacts on HIV Services Lilian Mworeko International Community of Women Living with HIV Eastern Africa (ICWEA), Uganda
10:00	Panel Discussion - The Impact of COVID-19 Pandemic on the Momentum Towards HIV/AIDS Epidemic Control in Uganda Lisa J. Nelson, MD, MPH, MSc Country Director, US Centres for Diseases Control & Prevention (CDC), Uganda Cissy Kityo Mutuluza, MD, PhD Executive Director, Joint Clinical Research Centre, Uganda Stephen Watiti, MD Board Chairperson, The National Forum of People Living with HIV/AIDS Networks in Uganda (NAPHOPANU), Uganda
10:20	Keynote Address Hon. Dr. Jane Ruth Aceng Ocero Minister of Health, Uganda
10:30	Refreshment Break and Poster Viewing



Session 2 COVID-19 and HIV Intersection - 2nd James Hakim Memorial Lectures

Chairs: Catherine Hankins and Guido Ferrari

11:00 **The Impact of COVID-19 on the HIV Cascade**
Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc, HonLLD Monash, DPMP
 University of Malaya, Malaysia

Virtual

11:25 **Adapting HIV Research and Training to COVID-19 Response**
Sikhulile Moyo, MSc, MPH, PhD
 Botswana Harvard AIDS Institute Partnership, Botswana
 Harvard T.H. Chan School of Public Health, United States

11:50 **Evolving COVID-19 Variants, Immune Escape, and Implications for Vaccination Program**
Salim Abdool Karim, FRS
 CAPRISA, South Africa

Virtual

12:15 **Q&A**

12:30 Lunch and Early-Career Investigator Meet-The-Expert Session

Oral Abstract Presentations I

Chairs: Lisa Mills and Sam Phiri

13:30	Effect of the COVID-19 Pandemic Restrictions on Outcomes of HIV Care Among Adults in Kampala City, Uganda	Jonathan Izudi, Uganda	#1
13:45	Increasing TB/COVID-19 Case Detection Through Diagnostics Program Integration	David Segun Adeniyi, Nigeria	#2
14:00	Low-Level of Archived Resistance to Integrase Inhibitors Among Third-Line Patients Under Dolutegravir-Based Regimens in Cameroon: Implications for Future Therapeutics	Ezechiel Ngoufack Jagni Semengue, Cameroon	#3
14:15	Prevalence of Adverse Birth Outcomes and External Birth Defects Among Women Living With HIV in Malawi	Joshua Smith-Sreen, Malawi	#4

14:30 **Q&A**

Session 3 COVID-19, Programmatic, Clinical, and Biological Interactions

Chairs: Jean Nachega and Edith Namulema

14:45 **Innovative TB Programming within the Context of COVID-19**
Lucica Ditiu, MD
 Stop TB Partnership, Switzerland

Virtual

15:10 **Biologic Interactions Between COVID-19 and HIV**
Penny Moore, PhD
 University of the Witwatersrand and National Institute for Communicable Diseases, South Africa

Virtual

15:35 **Q&A**

15:45 Conference Photo

16:00 Refreshment Break and Poster Viewing

Session 4 Improving Access to COVID-19 and HIV Medicines in Africa

Chairs: Timothy Mastro and Elizabeth Bukusi

16:30 **mRNA and HIV Vaccines: The Way Forward for Africa**

Larry Corey, MD

Fred Hutchinson Cancer Center / University of Washington, United States

Virtual

16:55 **Accessing COVID 19 Antivirals and New Long Acting Agents in Africa**

Tiwadayo Braimoh, MSc, MBA

Medicines Patent Pool, Switzerland

17:20 **Q&A**

Session 5 Opening Day Formal Debate: Unvaccinated People Should Be Denied Access to Public Spaces To Prevent COVID-19 Transmission Within the African Context

Chair: Peter Kilmarx

17:30 **Opening Words & Voting**

Peter Kilmarx, MD, FACP, FIDSA

John E. Fogarty International Center, National Institutes of Health, United States

17:35 **First Speaker For the Proposition**

Nelson Sewankambo, MBChB, MSc, MMed, FRCP, LLD (HC)

Makerere Medical School, Uganda

17:42 **First Speaker Against the Proposition**

François Venter, MD, FCP, PhD

Ezintsha, University of the Witwatersrand, South Africa

17:49 **Debate from the Floor**

18:11 **Second Speaker For the Proposition**

Nicholus Nanyeenya, MBChB, MPH

Ministry of Health CPHL, Uganda

18:15 **Second Speaker Against the Proposition**

Esther Bayiga, PhD(c)

School of Public health, Makerere University, Uganda

18:19 **Rebuttal**

Professors Nelson Sewankambo and François Venter

18:25 **Final Voting and Closing**

Peter Kilmarx, MD, FACP, FIDSA

John E. Fogarty International Center, National Institutes of Health, United States

18:30 Opening Reception



Wednesday, 11 May

Parallel Early Morning Sessions - Sign Up Required			
07:00	Grantspersonship - National Institute of Health/Fogarty International Geetha Bansal, Guido Ferrari, and Peter Kilmarx	Mentoring Tiwadayo Braimoh and Barbara Castelnovo	Guided Poster Tours Theme: Index Testing and Recent Infection
Session 6 HIV Prevention <i>Chairs: Nyaradzo Mgodli and Stephen Watiti</i>			
08:00	HIV Prevention Studies and Newer Technologies Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa		Virtual
08:25	Roll Out of New Prevention Technologies Sinead Delany-Moretlwe, MBBCh, PhD, DTM&H Wits RHI, University of the Witwatersrand, South Africa		Virtual
08:50	Q&A		
Oral Abstract Presentations II <i>Chairs: Moorine Sekadde and Fred Semitala</i>			
09:00	Moving from Rhetoric to Reality: Lessons Learned from Integrating Oral PrEP and Family Planning Services in Public Health Facilities in Nairobi, Kenya	Patricia Jeckonia, #5	Kenya
09:15	The Value of a Ring to Women in Kenya: A Willingness-to-Pay Study of the Dapivirine Vaginal Ring	Urbanus Kioko, #6	Kenya
09:30	Adverse Pregnancy and Infant Outcomes in a Trial of an Intervention for PMTCT and Family Health in Southwestern Kenya	Salome Ogola, #7	Kenya
09:45	Incidence of Intimate Partner Violence and Associated Risk Factors Amongst Pregnant and Breastfeeding Women Living with HIV in Malawi	Tapiwa Tembo, #8	Malawi
10:00	Q&A		
10:10	Refreshment Break and Poster Viewing		
10:40	Symposium I - JnJ		

Mini-Oral Abstract Presentations I

Chair: Joseph Baluku

11:40	Depression and Anxiety in Couples Enrolled in a Trial of an Intervention for PMTCT and Family Health in Southwestern Kenya	Joash Adongo, Kenya	#9
11:43	Collaboration with Traditional Birth Attendants in Akwa Ibom, Nigeria to Improve Access to HIV Testing Services Among Pregnant Women	Esther Nwanja, Nigeria	#10
11:46	Acceptability of Injectable Cabotegravir Versus Daily Oral TDF/FTC for PrEP: Lesson from HPTN 084	Juliane Etima, Uganda	#11
11:49	"You Tell Him that 'Baby, I am Protecting Myself'": Women's Agency, Constraint, Stigma and the Potential for PrEP Use in Durban, South Africa	Nonhlonipho Bhengu, South Africa	#12
11:52	Human Resources for Health: The Impact of Case Management Teams on Continuity of Treatment Among People Living with HIV (PLHIV) in Plateau State, Nigeria	Anita Ejideh, Nigeria	#13
11:55	Q&A		
12:10	Lunch and Early-career Investigator Meet-The-Expert Session		

Session 7 COVID-19 Response and Realities in Low Socioeconomic Settings

Chair: Philip Smith

13:30	Introduction Philip Smith, PhD Desmond Tutu Health Foundation, South Africa		
13:32	CSIGN - COVID-19 Surveillance Intensification in Ghana Network William Ampofo, PhD University Of Ghana / African Vaccine Manufacturing Initiative, Ghana		
13:39	MozCOVID - COVID-19 Surveillance in Rural Moz to Inform Prompt and Effective Response Inacio Mandomando, PhD Centro de Investigação em Saúde de Manhiça, Mozambique		
13:46	TRACE - Transmission of COVID-19 in Crowded Environments Philip Smith, PhD Desmond Tutu Health Foundation, South Africa		
13:53	COREP - Determining the Epidemiological Parameters of COVID-19 Through Sero-Surveillance with Dried Plasma Spots and Nested Household Transmission Studies in Rural Kenya and South Africa Till Bärnighausen, MD, ScD, MSc, MSc Harvard T.H. Chan School of Public Health / Wellcome Trust's Africa Health Research Institute, South Africa		
14:00	Q&A		
14:10	Refreshment Break and Poster Viewing		



Symposium II - GILEAD - Advanced HIV Disease (AHD)

Chair: Flavia Kiweewa

- 14:40 **Introduction**
Flavia Kiweewa, MBChB, MSc
Makerere University Johns Hopkins University MU-JHU Research Collaboration, Uganda
- 14:50 **AHD, Emerging/Neglected Opportunistic Infections Hiding in Plain Sight (The Nigeria Experience)**
Rita Oladele, MBBS, FMCPPath, MSc, PhD
College of Medicine University of Lagos, Nigeria
- 15:10 **Refocusing on What Really Matters – Advanced HIV Disease**
David Meya, MBChB, MMed, CTropMed, PhD
College of Health Sciences, Makerere University, Uganda
University of Minnesota, United States
- 15:30 **Q&A**

Session 8 Elimination of Mother to Child Transmission

Chair: Nadia Sam-Agudu

- 15:40 **State of the Art eMTCT**
Chewe Luo, MD, PhD
UNICEF, United States / University Teaching Hospital, Zambia
- 16:05 **Is eMTCT Feasible in Africa: Lessons from Botswana**
Eldah Dintwa
Ministry of Health and Wellness, Botswana
- 16:30 **Q&A**

Virtual

Session 9 Innovative HIV Testing Approaches

Chair: Maria Sarah Nabaggala

- 16:40 **Innovations in HIV Testing: Sexual Network Testing and Recency Testing**
Andrew Auld, MD, MSc, PhD
The Global Fund, United States
- 17:05 **Q&A**

Virtual

17:15 **Closure of Day 2**

Thursday, 12 May

Parallel Early Morning Sessions - Sign Up Required

07:00	Grantpersonship ANRS-Maladies infectieuses émergentes & AFREhealth Jean Nachega & Laure-Amelie de Monteynard	Mentoring Peter Kilmarx & Nadia Sam-Agudu	Guided Poster Tours Theme: HIV and Coinfections, HIV in Women
-------	---	--	--

Session 10 HIV Care and Treatment Chair: Andrew Kambugu

- 08:00 **Switching When Detectable with/out Resistance Testing**
Nickolas Paton, MD, FRCP
National University of Singapore, Singapore
- 08:25 **What Rx to Start, PH Approach vs Individualized Therapy**
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
- 08:50 **Q&A**

Mini-Oral Abstract Presentations II Chair: Chris Akolo

- | | | | |
|-------|---|---|-----|
| 08:55 | Dolutegravir-Based Regimen Ensures High Virological Success Despite Prior Exposure to Efavirenz-Based First-Line ART: a Comparative Study in Cameroon | Ngoufack Jagni
Semengue,
Cameroon | #14 |
| 08:58 | Assessing the Impact of COVID-19 on HIV Virological Suppression in the Public Health Sector in South Africa | Somayya Sarang,
South Africa | #16 |
| 09:01 | Do Integrase Strand Transfer Inhibitors Increase the Risk of Developing Diabetes Mellitus Type 2 Among Adult People Living with Human Immunodeficiency Virus as Compared to Other Antiretroviral Therapy? A Systematic Review and Meta-Analysis | Violet Dismas
Kajogoo,
Tanzania | #17 |
| 09:04 | High Transmitted Drug Resistance in Brazil: Unprecedented Levels of INSTI Resistance | Ricardo Diaz,
Brazil | #18 |
| 09:07 | Q&A | | |

Symposium III - ViiV - Real World Experience of Paediatric HIV Management "An African Perspective"

- 09:25 **Welcome and Introduction**
Ismaeel Ebrahim, MD
ViiV Healthcare / GSK, South Africa
- 09:35 **ART Failure and Challenges Managing CLHIV, a Ugandan and Kenyan Perspective**
Victor Musiime, MBChB, MMed, PhD
Makerere University College of Health Sciences, Uganda
Joseph Mbuthia, MBChB, MMed
ViiV Healthcare / GSK, Kenya
- 10:10 **Q&A**

- 10:25 Refreshment Break and Poster Viewing



Symposium IV - Viartis - TAF Based ART – Experience in High- and Low-Income Countries

10:55 **Welcome Address**

11:00 **VIEND Study**

Lloyd Mulenga, BSc(HB), MBChB, MSc, MMed, PhD

Ministry of Health, Zambia

11:15 **Experience in Botswana**

Ava Avalos, PhD

SANTHE / Careena Centre for Health/ Botswana Harvard AIDS Institute Partnership (BHP), Botswana

11:30 **Experience in High Income Countries**

11:45 **Q&A**

Mini-Oral Abstract Presentations III

Chairs: Timothy Mastro and Nadia Sam-Agudu

11:55	Does Differentiated Service Delivery for HIV Treatment Change Healthcare Providers Workload? Provider Views from Malawi, South Africa, and Zambia	Bevis Phiri, Zambia	#19
11:58	Shifting from 3-Multimonth Prescribing (3MMP) to 6-Multimonth Prescribing (6MMP) Was Associated with Non-Inferior Outcomes for Adults on Antiretroviral Therapy in Rwanda	Brian Kwizera, Rwanda	#20
12:01	Risk Factors for Frailty in a Geriatric Cohort on Long Term Antiretroviral Treatment in Uganda	Phoebe Mbabazi, Uganda	#21
12:04	Accelerating HIV Epidemic Control in Benue State, Nigeria, 2019-2021: The APIN Program Experience	Mikhail Obaje, Nigeria	#22
12:07	Community Antiretroviral Therapy Dispensation in Cameroon Associated with Superior Client Outcomes: A National Evaluation	Anastasie Mapassion Ng, Zambia	#23
12:10	Q&A		

12:25 Lunch and Early-career Investigator Meet-the-Expert Session

Session 11 Addressing COVID-19 Setbacks Among Women Professionals: Supporting Gender Sensitive Resilient Strategies

Chair: Catherine Hankins

13:25 **Panel Discussion**

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD

Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa

Pauline Byakika-Kibwika, MBChB, MSc, MMed, PhD

Makerere University College of Health Sciences, Uganda

Rhoda Wanyenze, MBChB, MPH, PhD

Makerere University College of Health Sciences, Uganda

Virtual

13:50 **Q&A**

Symposium V - Johnson and Johnson - What is the Future of Long-Acting ARV Injection Therapies

Chair: Mercy Wali

- 13:55 **Welcome and Introduction**
Mercy Wali, MD
Medical Education Lead, Johnson and Johnson Global Public Health, Kenya
- 14:00 **What is the Future of Long-Acting ARV Injection Therapies**
Kogieleum Naidoo, MBChB, PhD
Centre for the AIDS Program of Research in South Africa (CAPRISA), South Africa
- 14:45 **Q&A**

14:55 Refreshment Break and Poster Viewing

Mini-Oral Abstract Presentations IV

Chair: Kwasi Torpey

- | | | |
|-------|--|--------------------------------------|
| 15:25 | Directly Observed Therapy (DOT) for ART in Children to Attain Viral Suppression | Evelyn Matongo, #24
Zambia |
| 15:28 | Leaving No One behind: The Impact of Kindergarten ART clinic on HIV Treatment Outcomes Among Children Enrolled in Kindergarten HIV Program at Lighthouse HIV Care Facilities | Ackim Sankhani, #25
Malawi |
| 15:31 | Supporting Self-Management in Adolescents to Be Resilient and Thrive: an Intervention Development Study | Talitha Crowley, #26
South Africa |
| 15:34 | Une Entrée Difficile Dans la Sexualité Pour les Adolescentes Séropositives au Sénégal, Entre Normes Sociales et VIH | Maimouna Diop, #27
Senegal |
| 15:37 | Risks and Vulnerabilities Among Adolescent Girls and Young Women Accessing HIV Prevention Services at DREAMS Centers in Zambia | Namukale Nanyangwe, #28
Zambia |
| 15:40 | Q&A | |

Session 12 HIV in Children and Adolescents

Chair: Sabrina Bakeera-Kitaka

- 15:55 **Dolutegravir Treatment Outcomes in Children Including Neonates**
Victor Musiime MD, MMed, PhD
Makerere University College of Health Sciences, Uganda
- 16:20 **Differentiated Care Services including Mental Health for Adolescents**
Nicola Willis, MPhil
Africaid, Zvandiri, Zimbabwe
- 16:45 **Q&A**



Session 13 HIV and Comorbidities

Chairs: Elly Katabira and Christine Sekaggya

16:55 **Progress in Treatment for Viral Hepatitis - What are the Implications for Treatment**

Jürgen Rockstroh, MD

HIV Outpatient Clinic, University of Bonn, Germany

17:20 **HIV, Non-Communicable Disease, and Aging**

Barbara Castelnuevo, MD, PhD

Infectious Diseases Institute, Uganda

17:45 **Q&A**

Virtual

Closure of Day 3

Friday, 13 May

Parallel Early Morning Sessions - Sign Up Required				
07:00	Grantpersonship General Kwasi Torpey & Nadia Sam-Agudu	Mentoring Nyaradzo Mgodli & François Venter	Guided Poster Tours Theme: Key populations, COVID-19, Implementation Science and HIV	
Mini-Oral Abstract Presentations V <i>Chairs: Sam Phiri and Eldah Dintwa</i>				
08:00	Effectiveness of Innovative Index Testing Strategies: The Case of a CSO in Western Region of Ghana		Mark Owusu, Ghana	#29
08:03	Traditional Healer Delivered Support Improves Re-Linkage to Care and ART Adherence Among Defaulted PLWH in Rural Uganda		Matthew Ponticiello, United States	#30
08:06	Behavioral Economic Incentives to Support HIV Treatment Adherence (BEST): One-Year Results of a Randomized Controlled Trial in Uganda		Peter Wabulaka, Uganda	#31
08:09	Retention and Access to Viral Load of Key Populations Living with HIV (KPLHIV) : Cases of MSM Followed by the NGO SOUTOURA/EpiC in Mali		Almahdi Ag Alitini, Mali	#32
08:12	Impact of COVID-19 Public Health Measures on ART Use Among Ugandans Living with HIV in Sero-Different Couples		Timothy Ronald Muwonge, Uganda	#33
08:15	Q&A			
Session 14	Structural Issues : Stigma and Discrimination <i>Chair: LaRon Nelson</i>			
08:30	Addressing Stigma in Health Facilities: Why It Matters and How It Can be Done Laura Nyblade, PhD RTI International, United States			
08:50	Q&A			
Symposium VI - ANRS-Maladies infectieuses émergentes <i>Chair: Jean Nachega</i>				
09:00	From HIV to Emerging Infectious Diseases, a Research Agency for Preparedness and Response Eric D'Ortenzio, MD, MPH ANRS-Maladies infectieuses émergentes, France			
09:25	Q&A			
Session 15	KP Programming <i>Chair: LaRon Nelson</i>			



09:30 **Achieving HIV Epidemic Control Among KPs in Africa**

Christopher Akolo, MD, MSc, FWACP

FHI 360, United States

09:55 **Lessons and Experiences from the Pioneer Medically Assisted Therapy (MAT) - Program for PWID in Uganda**

Peter Mudiope, MD

Ministry of Health, Uganda

10:20 **Q&A**

10:25 Refreshment Break and Poster Viewing

Session 16 OVC Programming

Chair: Peter Kilmarx

10:55 **State of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs**

Grace Mayanja

FHI 360, Ethiopia

11:20 **Q&A**

Session 17 HIV and HPV

Chair: Sabrina Bakeera-Kitaka

11:25 **Introductions and Objectives**

Sabrina Bakeera-Kitaka, MBChB, MMed, PhD

Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda

11:30 **HPV-Related Diseases in People Living with HIV: Challenges in Clinical Management And Prevention Opportunities (Screening and Vaccination)**

Hennie Botha, MBChB, FCOG, MMed, PhD

Stellenbosch University, South Africa

11:50 **Integrating HPV Prevention in Adolescent HIV Care: Example of Friday Adolescent Clinic at Makerere University**

Sabrina Bakeera-Kitaka, MBChB, MMed, PhD

Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda

12:10 **Q&A**

Mini- Oral Abstract Presentations VI

Chairs: Elly Katabira and Grace Mayanja

12:25	OK to Not Be OK in HIV Care: Lessons and Outcomes of Integration of Mental Health Screening, Referrals and Support in Routine HIV Care in Zimbabwe	Efison Dhodho, Zimbabwe	#34
12:28	Factors Associated with Low Tuberculosis Case Notification and Treatment Success at Health Facilities in Zambia: A Cross Sectional Study	Tikulirekuti Banda, Zambia	#35
12:31	Factors Shaping Access to TB Testing among Adolescents Living with Human Immunodeficiency Virus in the Eastern Cape, South Africa	Siyanai Zhou, South Africa	#36
12:34	Immunological Phases of Sepsis in a Ugandan Cohort with Significant HIV Co-Infection	Pritch Kagera Kabata, Uganda	#37
12:37	High Prevalence of the Atypical Hepatitis B Virus Serology Profile: HBsAg Positive/Anti-HBc Negative in HBV and HIV Co-Infected People in Botswana	Bonolo Bonita Phinius, Botswana	#38

12:40 **Q&A**

Closing Session

12:55	Presentation of the Joep Lange & Charles Boucher Awards to the Highest Scoring Abstract by Early-Career African Scientists		
13:05	Reflections by the Chairs of the 16th INTEREST Conference Kwasi Torpey, MD, PhD, MPH, FGCP, FWACP University of Ghana, Ghana <i>Scientific Chair</i> Elly Katabira, MD, FRCP Makerere University College of Health Sciences, Uganda <i>Conference Co-Chair</i> Sabrina Bakeera-Kitaka, MBChB, MMed, PhD Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda <i>Local Co-Chair</i> Andrew Kambugu, MBChB, MMed, FRCP Infectious Diseases Institute, Uganda <i>Local Co-Chair</i>		

13:15 End of the Conference



Faculty_____



Invited Speaker

**Salim Abdool Karim,
FRS**

CAPRISA,
South Africa

Salim Abdool Karim (FRS) is a South African clinical infectious diseases epidemiologist widely recognized for scientific contributions and leadership in AIDS and Covid-19. He is Director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, and CAPRISA Professor of Global Health at Columbia University, New York.

He is adjunct Professor of Immunology and Infectious Diseases at Harvard University, adjunct Professor of Medicine at Cornell University and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal. He previously served as President of the South African Medical Research Council.

He is a member of the African Task Force for Coronavirus and a Commissioner on the Lancet Commission on Covid-19. He was the Chair of the South African Ministerial Advisory Committee on COVID-19.

No Information



Local Organising Committee

**Tracy Ahumuza,
B.A.Com**

Infectious Diseases Institute,
Uganda

Tracy Ahumuza is a communications professional with over 10 years' experience in public relations, broadcast and print journalism. She has training in health promotion and public health communication.

She currently works with the Infectious Diseases Institute as the corporate communications specialist and supports Ministry of Health Risk Communication strategies. Her passion for neonatal and maternal health led her to start, ATTA Breastmilk Community, a project of the Alyssa Marie Foundation, a not-for-profit organisation which has a mandate to support parents with accurate and compassionate information to make an informed decision in their new-born's life.

ATTA is dedicated recruiting breast milk donors and advocating for Uganda where safely donated, pasteurised, screened and stored breast milk is available for all sick, preterm, low birth weight and new-borns who have lost their mother and/or could be saved by this milk.

No potential conflict of interest to report



Invited Speaker
Christopher Akolo,
MD, MSc, FWACP
FHI 360,
United States

Christopher Akolo, is an infectious disease physician, currently with FHI 360 as a Technical Director with the PEPFAR/USAID-funded Meeting Target and Achieving Epidemic Control (EpiC) project currently being implemented across over 35 countries globally.

He has over 27 years of clinical experience, including over 20 years' experience with implementation of HIV prevention, care, and treatment programs in resource limited settings and provision of HIV services to key populations (KP), especially men who have sex with men and female sex workers.

Within the past 16 years, he has supported the U.K. Medical Research Council's HIV research program in The Gambia, worked as a clinician with the HIV Unit/Jefferiss Wing of St. Mary's Hospital, Paddington, London, served as the Technical Advisor clinical mentoring and medical education with the Institute of Human Virology (IHV) at the University of Maryland Baltimore, and has been part of several global teams, including those that revised the current WHO STI Guidelines, WHO KP Guidelines, and the current WHO guidelines on isoniazid preventive therapy.

His areas of interest include KP programming, antiretroviral therapy, HIV treatment failure, PrEP, TB, STI services, operations research, and stigma reduction within health facilities.

No potential conflict of interest to report



Invited Speaker
Andrew Auld,
MD, PhD, MSc
The Global Fund,
United States

Andrew Auld has about 20 years of experience in global public health in under-served settings in Africa, Southeast Asia, and the Caribbean. Since 2021, Dr. Auld has served as a Senior Disease Advisor within the HIV Team, as part of the COVID-19 Response Mechanism, at The Global Fund, Geneva. In this role, he serves as the HIV team focal point for laboratory and analytics, including analysis of COVID-19 interruptions and adaptations in global HIV programs.

From 2016 to 2021 he was the CDC Country Director in Malawi, where he supported the overall strategic direction for CDC Malawi, and facilitated increased funding levels from about \$40 million/year in 2016 to over \$100 million/year in 2021. During this time CDC Malawi supported the Ministry of Health and other stakeholders to accelerate towards HIV epidemic control, reaching 88-98-97 by 2021.

During 2009-2016, Dr. Auld served as a Medical Officer at CDC Atlanta, supporting global HIV and TB programs. He joined CDC as an Epidemic Intelligence Officer in 2007 and was awarded the Paul C. Schnitker award for extraordinary contributions to global public health by an EIS officer. Dr. Auld began his public health career with UNICEF in Indonesia following the 2004 Indian Ocean tsunami where he helped lead integrated health campaigns providing measles vaccinations, vitamin A, and insecticide-treated nets across several provinces in Sumatra.

Dr. Auld has received several public health awards including two first-author Charles C. Shepard Science awards from CDC in 2021, and the London School of Hygiene and Tropical Medicine Woodruff medal for the PhD thesis most likely to lead to alleviation of suffering in tropical or developing countries in 2020.

Dr. Auld is a licensed general medicine practitioner from South Africa (University of Cape Town) and the United Kingdom and has completed the United States Medical Licensure Exams (USMLE). In addition he has completed Master of Science and PhD degrees in Epidemiology through the London School of Hygiene and Tropical Medicine (LSHTM).

No potential conflict of interest to report



International Conference Committee

Jean B. Nachega,
MD, PhD, MPH, FRCP, FAAS

University of Pittsburgh /
Johns Hopkins University,
United States Stellenbosch
University, South Africa

Jean B. Nachega is an Infectious Diseases-Internist and Epidemiologist and a Professor Extraordinary of Medicine at Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa.

He is also a tenured Associate Professor of Medicine, Infectious Diseases, Microbiology and Epidemiology, at Graduate School of Public Health, University of Pittsburgh, PA, USA as well as an Adjunct Associate Professor of Epidemiology and International Health at Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

He has over 30 year-experience in patient care, teaching, designing, and implementing HIV/AIDS and Tuberculosis studies or programs funded by NIH/ NIAID, NIH/FIC, Wellcome Trust, PEPFAR, and EDCTP. He authored more than 200 peer-reviewed publications including in top-tier journals such as The Lancet, The New England Journal of Medicine, JAMA, Clinical Infectious Diseases and Annals of Internal Medicine.

He is an ad hoc consultant at WHO, CDC, Bill and Melinda Gates Foundation, member-elect of the Academy of Sciences of South Africa (ASSAf) and the African Academy of Sciences (AAS).

No potential conflict of interest to report



Local Co-Chair

**Sabrina
Bakeera-Kitaka,**
MBChB, MMed, PhD

Makerere University College
of Health Sciences / Mulago
National Referral Hospital,
Uganda

Sabrina Bakeera-Kitaka is a Senior Lecturer at the Department of Paediatrics and Child health at the Makerere University, College of Health Sciences.

She completed her MBChB in 1995; Masters of Paediatrics and Child Health in July 2002 both at Makerere University. She was a Gilead Fellow, and then Research Scholar at the Infectious Diseases Institute from 2003-2011 where she undertook a Fellowship in Paediatric Infectious Diseases and did research on HIV-infected adolescents.

She has a Ph.D. from the School of Biomedical Sciences at the University of Antwerp, Belgium. She is involved in conducting basic research in various Paediatrics Infectious Diseases and offers clinical care to HIV infected children and adolescents most of whom are perinatally infected. She directs the Adolescent Health training program at the Makerere University College of Health Sciences and is the Founder President of the Society of Adolescent Health in Uganda (www.sahu.ug).

Dr. Kitaka is also an active member of the African Paediatric Society of Infectious Diseases (AFSPID).

No potential conflict of interest to report



Invited Speaker

Esther Bayiga, PhD(c)

School of Public health,
Makerere University,
Uganda

Esther Bayiga is a PhD candidate at the School of Public health, Makerere University (MakSPH). Her PhD research funded by the German Federal Ministry of Education focuses on pedestrian safety and the built environment in Kampala city, Uganda. She is also a research fellow in the department of Disease Control and Environmental health and in her research unit, she specializes in road safety research with about 7 years' experience.

Esther has a master's degree in Health Services Research from MakSPH with a focus on road safety. She was a 2015-2016 NIH Fogarty fellow under the Johns Hopkins-Makerere University collaboration on Trauma, Injury and disability research.

She is also the past secretary of the PhD forum at the Makerere University School of Public Health. Her research interests include; injury epidemiology and road safety research with focus the built environment, post-crash emergency care, costing of health interventions and evaluation of their effectiveness.

No potential conflict of interest to report



International Conference Committee

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD

Desmond Tutu Health
Foundation / University
of Cape Town,
SouthAfrica


Linda-Gail Bekker is the Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town and Chief Executive Officer of the Desmond Tutu Health Foundation. She is a physician scientist and infectious disease specialist.

Her research interests include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and MSM. Bekker has also recently been involved in a number of COVID19 vaccine trials and co-leads the Sisonke Phase 3B study which has seen the vaccination of 500 000 health care workers in South Africa. She has led numerous investigator-driven studies in HIV treatment, prevention and tuberculosis.

She is a past president of the International AIDS Society and served as the International Co-Chair of the 9th IAS Conference and 22nd International AIDS Conference and Co-Chaired the Research 4 Prevention Conference that was held in January 2021.

Potential conflict of interest:

Gilead, JnJ, Merck, and ViiV



Invited Speaker

Hennie Botha,
MBChB, FCOG, MMed, PhD

Stellenbosch University,
South Africa

Professor Hennie Botha is the Head of Department of Obstetrics and Gynaecology at Stellenbosch University and Tygerberg Hospital in South Africa. He started his professional career in a rural hospital in Malawi. Returning to South Africa he specialised in Obstetrics and Gynaecology and then did further training in the field of Gynaecological Oncology in the United Kingdom. He has authored and co-authored many articles in journals and is co-editor of the textbook "Clinical Gynaecology".

His research focus is on cervical cancer prevention and treatment, including in people living with HIV. He collaborates with national and international researchers.

Prof. Botha is enthusiastic about under-and postgraduate teaching and training and his unit has trained many specialists in South Africa and other African countries.

No potential conflict of interest to report



Invited Speaker

Tiwadayo Braimoh,
MSc, MBA

Medicines Patent Pool,
Switzerland

Tiwadayo Braimoh joined the Medicines Patent Pool in February 2021 as Policy and Advocacy Manager. After 9 years of working in sales, marketing, and business development in the pharmaceutical industry, Tiwadayo joined Clinton Health Access Initiative in 2013 where he held several positions in Nigeria and Rwanda, mainly focusing on access and health policy.

His last position was as Senior Technical Advisor for Health Financing at the Ministry of Health, Rwanda. At MPP, he works on the policy aspects of COVID-19 with a focus on Africa. Tiwadayo holds a MSc in Health Policy, Planning, and Financing from the London School of Economics and London School of Hygiene and Tropical Medicines and an MBA from the University of Lagos. He is also a Pharmacist and Fellow of the West African Postgraduate College of Pharmacists.

No potential conflict of interest to report



International
Conference Committee

**Elizabeth Anne
Bukusi,**
**MBChB, M.Med (ObGyn),
MPH, PhD, PGD (Research
Ethics), MBE (Bioethics), CIP**
Kenya Medical Research
Institute, Kenya

Professor Elizabeth Anne Bukusi (ObGyn), MPH, PhD, PGD (Research Ethics), Masters in Bioethics, Fellow of the African Academy of Sciences, earned her general medical degree and Masters in Obstetrics and Gynecology degree from the University of Nairobi. She then earned a certificate in international health, MPH and a PhD from the University of Washington's Department of Epidemiology; a post graduate diploma in Research Ethics from the University of Cape Town and a Masters in Bioethics from Centre for Bioethics and Culture at the Sind Institute of Urology and Transplantation in Karachi. She is a certified IRB Professional. She is a Senior Principal Clinical Research Scientist at the Kenya Medical Research Institute (KEMRI), a Research Professor at the University of Washington (Departments of Obstetrics and Gynecology and Global health), an honorary lecturer at Aga Khan University in Nairobi And Maseno University (Department of Obstetrics and Gynecology) and Volunteer Clinical faculty – Professor at the University of California San Francisco (Department of Obstetrics, Gynecology & Reproductive Sciences).

Prof. Bukusi, in collaboration with Dr. Craig Cohen at UCSF, established the KEMRI Research Care and Training Program in 1995. In addition to her substantial experience in conducting socio-behavioral and biomedical research and providing HIV care, mentoring and training health care and research personnel to enhance local and international capacity, she has a strong interest in research and clinical ethics and the development of systems and structures for regulation of research at KEMRI and in the country. She is the chairperson of the National Bioethics Society of Kenya, (BSK), a multidisciplinary, non-political, non-discriminatory, and not-for-profit organization with a primary objective to promoting high ethical standards in bio-medical research, medicine and health care in Kenya. She is a board member of AVAC, Chaired the WHO HRP Alliance (capacity building for RH research), and is a trustee for the HIV Trust, and an Elected Fellow of the African Academy of Sciences (FAAS).

Potential conflict of interest:
Merck/MSD and ViiV



Invited Speaker

**Pauline
Byakika-Kibwika,**
**MBChB, MSc, MMed, PhD,
FRCPE**

Makerere University College
of Health Sciences, Uganda

Prof Pauline Byakika-Kibwika is an Internal Medicine Specialist and Epidemiologist with sub specialization in infectious diseases. She is the Chair of the Department of Medicine at Makerere University College of Health Sciences. She graduated with a Bachelor of Medicine and Bachelor of Surgery (MBChB) degree, a Master of Science (MSc) in Clinical Epidemiology and Biostatistics, and a Master of Medicine (MMed) degree in Internal Medicine, from Makerere University. She holds a Doctor of Philosophy (PhD) in Clinical Pharmacology obtained from Trinity College Dublin, Ireland. Pauline is Fellow of the Uganda National Academy of Sciences and Fellow of the Royal College of Physicians of Edinburgh.

Her research focused on optimizing treatment for HIV and malaria and strengthening biomedical research capacity through the establishment of a clinical pharmacology research unit and laboratory at the Infectious Diseases Institute in Kampala, Uganda, where she conducted research to investigate the pharmacokinetic profiles and drug interactions of antiretroviral and antimalarial drugs in an African population. In 2006, she was selected as one of 5 Sewankambo Scholars, a prestigious scholarship program named after one of Uganda's most distinguished researchers, aimed to develop independent Principal Investigators in Uganda. Since then she has written successful research grants, conducted and managed research projects including clinical trials, published several articles in peer reviewed journals, mentored and supervised students' research at post graduate and PhD levels at Makerere University.

Pauline has worked on various in country assignments with the Ministry of health, as part of the National Malaria Control Program and is a member of the Ministerial Scientific Advisory Committee on COVID-19. She served as the Vice President of the Uganda Medical Association, a professional body, that champions medical doctors' interests, welfare and advocates for quality health service delivery in the country. She served as Medical Advisor to the Oil and Gas Industry in Uganda, specifically; Tullow Oil Uganda Pty and TOTAL Exploration and Production. At the East African Regional level; she is a Commissioner on the Board of the East African Health Research Commission (EAHRC), which is the principal advisory institution to the East African Community on Health Research and Development.

No potential conflict of interest to report



Local
Organising Committee
Barbara Castelnovo,
MD, PhD
Infectious Diseases Institute,
Uganda

Barabara Castelnovo is a researcher who has been working at the Infectious Diseases Institute (IDI), Uganda, for 18 years.

She is the currently the Head of the Research Department, which hosts over 150 projects, and she has worked in several roles at IDI as a senior medical officer, study coordinators and thereafter assuming leadership roles. She obtained her Medical Degree and Master in Infectious Diseases at the University of Milan, and a PhD degree from the University of Antwerp (Belgium) while working at IDI. She has a long track record in implementing clinical research and models of delivering HIV care, both for observational studies and clinical trials in HIV medicine including co-morbidities.

In the last five years has also been the Head of the Research Capacity Building Units, which hosts and support Ugandan scholars from 5 different capacity building grants, and foreign students from international collaborating Institution. She has personally mentored master and PhD students, with currently 4 PhDs and 4 master students under her direct supervision. She is the recipient of a senior fellowship from EDCTP on HIV and aging, aiming to build capacity for geriatric medicine in Uganda and characterize geriatric syndrome in people aging with HIV.

No potential conflict of interest to report



Invited Speaker
Larry Corey,
MD
Fred Hutchinson Cancer
Center / University of
Washington,
United States

Larry Corey is a Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center and a Professor in Medicine and Laboratory Medicine at the University of Washington. Dr. Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer.

He is the founder and principal investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trials sites in 16 countries on five continents. Dr. Corey is also the principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) and co-leads the Network's COVID-19 vaccine testing pipeline.

Dr. Corey is a member of the US National Academy of Medicine and the American Academy of Arts and Sciences.

He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor, or editor of over 1000 scientific publications.

No potential conflict of interest to report



Invited Speaker

**Sinead
Delany-Moretlwe,**
MBBCh, PhD, DTM&H

Wits RHI, University of the
Witwatersrand South Africa

Sinead Delany-Moretlwe is Associate Professor and Director: Research at Wits RHI. A South African-born medical doctor, her experience is primarily in sexual and reproductive health and HIV prevention research.

Currently she is a principal investigator on a large phase III trial of injectable cabotegravir as PrEP, and three demonstration projects of PrEP for adolescent girls and young women, with a particular focus on evaluating interventions that may address the social and structural barriers to PrEP use in young women. She is also technical lead on a PEPFAR Innovations award to strengthen testing and linkage to treatment and prevention in adolescents.

No potential conflict of interest to report



Invited Speaker

Eldah Dintwa

Ministry of Health and Well-
ness, Botswana

Eldah N. Dintwa is a Chief Health officer (CHO) overseeing HIV Prevention Programs in HIV/ AIDS Division, Department of Health Service Management, Ministry of Health and Wellness, Botswana. She holds a Master of Public Health from Monash University, Melbourne, Australia, Bachelor of Nursing science and Post basic Diploma in midwifery from University of Botswana. She has done several PMTCT courses including PMTCT basic training course, Training of Trainers (TOT), Infant and Young Child Feeding in the context of HIV, Early infant Diagnosis Master training among other courses.

She worked in several Primary Hospitals in Botswana as a midwife and TOT for PMTCT program for many years. She has been part of the PMTCT district team providing training, mentorship and support to the health care providers to implement decentralised PMTCT services. She was later transferred to the Ministry of Health and Wellness as PMTCT officer and given responsibility to be National PMTCT coordinator for six (6) years and Botswana has been awarded a Silver Tier for Path To Elimination under her leadership.

She has a long term goal of driving elimination of mother to child transmission agenda and want to use her untiring commitment and passion to attain the highest certification in the eMTCT before her retirement from public services.

No potential conflict of interest to report



Invited Speaker

**Lucica Ditiu,
MD**

Stop TB Partnership,
Switzerland

Lucica Ditiu, Executive Director of the Stop TB Partnership is a Romanian physician, accomplished professional and leader in the global fight against tuberculosis (TB) and other communicable diseases.

Dr. Ditiu is driven by the firm belief that we should “leave no one behind” and is one of the strongest advocates within the international community in the fight against tuberculosis.

A firm believer in innovation, flexibility, change, breaking the rules and thinking out of the box, Dr. Ditiu is dedicated to driving political commitment and engagement to accelerate the efforts to End TB.

No potential conflict of interest to report



International Conference Committee

**Guido Ferrari,
MD**

Duke University,
United States

Dr. Ferrari is Professor at Duke University in the Department of Surgery and Molecular Genetics and Microbiology. He is also affiliated faculty at the Duke Global Health Institute, Duke Human Vaccine Institute, and Honorary Professor at the University of Cape Town Department of Immunology.

Dr. Ferrari has worked on testing samples from vaccine recipients for cytotoxic T lymphocyte (CTL) and antibody dependent cellular cytotoxic (ADCC) responses for the HIV Vaccine Trial Network (HVTN), the Comprehensive Antibody-Vaccine Immune Monitoring Consortium (CA-VIMC) and for the Primate AIDS Vaccine Evaluation Group (PAVEG). He is currently the Director of the Center for AIDS Research Immunology Core and Mentoring Committee. He was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses and the difference in class I-restricted epitope recognition between HIV-1 infected individuals and vaccine recipients.

He followed this initial epitope mapping of cellular responses with the epitope mapping of ADCC responses to identify the anti-C1C2 epitope as the most recognized epitope by ADCC Ab responses in infected individuals. Dr. Ferrari has also been the organizer of 10 Symposia and numerous workshops to strength collaborations amongst more than 300 young African scientists in collaboration with Prof. Clive Gray at the University of Cape Town.

No potential conflict of interest to report



International
Conference Committee

Catherine Hankins,
MD, PhD, FRCPC, CM

McGill University / Amsterdam
Institute for Global Health and
Development, Canada

Catherine Hankins is Professor of Public and Population Health, Faculty of Medicine, McGill University; Deputy Director, Science at the Amsterdam Institute for Global Health and Development, Department of Global Health, University of Amsterdam; and Honorary Professor, London School of Hygiene and Tropical Medicine.

She has authored over 250 peer-reviewed publications and reviewed for scientific journals and funding agencies in Canada, USA, Africa, and Europe. As UNAIDS's first Chief Scientific Adviser, she led the scientific knowledge translation team, developing ethical and participatory HIV prevention trial conduct guidelines and convening mathematical modelling teams to support country implementation of proven biomedical HIV prevention modalities.

She was the editor of UNAIDS' popular science blog HIV This Week. Professor Hankins was Scientific Chair of the annual INTEREST conference in Africa from 2014 to 2020. She chairs the European and Developing Countries Clinical Trials Partnership's Scientific Advisory Committee and the Scientific Advisory Group of the USA National Institutes of Health HIV Prevention Trials Network.

She is a trustee of the HIV Research Trust, member of the International AIDS Society Industry Liaison Forum, and board member of AVAC. She is co-Chair of Canada's COVID-19 Immunity Task Force. She was named to the Order of Canada in 2013.

Potential conflict of interest:

Gilead, Merck, and ViiV



Invited Speaker

**Adeeba
Kamarulzaman,**
MBBS, FRACP, FAMM, FASc,
HonLLD Monash, DPMP

University of Malaya,
Malaysia

A graduate of Monash University and trained in Internal Medicine and Infectious Diseases in Melbourne Australia, Dr. Adeeba Kamarulzaman established the Infectious Diseases Unit at the University of Malaya Medical Centre.

She was Dean of the Faculty of Medicine, University of Malaya from 2011-2020 and is an Adjunct Associate Professor at Yale University. Dr. Kamarulzaman has been a committee member of several regional and international organizations including TREAT Asia, the International Society of Infectious Diseases, and was Co-Chair of the WHO Strategic and Technical Advisory Group on HIV (2012-2016).

She is presently the president of the International AIDS Society and has been appointed as a member of the World Health Organisation (WHO) Science Council.

Potential conflict of interest

Sanofi, Allianz Bhd, Frontiers Biotech, and Zuellig Pharma



Local Co-Chair

Andrew Kambugu,
MBChB, MMed, FRCP

Infectious Diseases Institute,
Uganda

Andrew Kambugu is the Sande-McKinnell Executive Director at the Infectious Diseases Institute (IDI), College of Health Sciences, Makerere University, Kampala, Uganda. He is an adjunct Associate Professor at the University of Minnesota, USA, and honorary Senior Lecturer in the Department of Medicine at Makerere University.

He received his basic medical training as well as his Masters in Internal Medicine at Makerere University in Uganda and undertook specialist training in infectious diseases at the University of Utah, USA, and the University of Manitoba, Winnipeg, Canada. He is a Fellow of the Royal College of Physicians of the United Kingdom. Dr. Kambugu previously served as the Head of the Research Program Prevention Care and Treatment Programmes at the IDI.

He has over 14 years of HIV clinical and programming experience and is a member of two national HIV subcommittees of the Ugandan Ministry of Health. He has made significant research contributions in the areas of antiretroviral therapy and opportunistic infections and has over 130 publications in peer-reviewed journals.

Potential conflict of interest

ViiV, Abbvie, and MSD



Conference Co-Chair

Elly Katabira,
MD, FRCP


Makerere University College
of Health Sciences,
Uganda

Elly Katabira, is Professor of Medicine in the School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Dr. Katabira received his medical degree at Makerere University and specialized in Neurology in England. Since 1985, he has worked in the field of HIV as a clinician, an educator, and a researcher. Dr. Katabira started the first AIDS clinic in Africa in 1987 and is a co-founder of TASO (The AIDS Support Organization) that has provided community-based support, care, and training for people living with HIV in Uganda and beyond. He has worked with international organisations including World Health Organisation (WHO) and United Nations Joint Programme on HIV/AIDS (UNAIDS).

He joined the International AIDS Society (IAS) in 1990 and became its Governing Council's Africa regional representative in 2000. He was the IAS President from July 2010 to July 2012. Dr Katabira's research interests are in clinical trials, operational research, and antiretroviral treatment implementation studies.

He has published over 250 papers in peer-reviewed journals and presented over 250 abstracts at international conferences. In recognition of his contributions in the HIV field, he was elected an honorary international member of the American Academy of Arts and Sciences in 2017.

No potential conflict of interest to report



International Conference Committee

Peter Kilmarx,
MD, FACP, FIDSA

John E. Fogarty International
Center, National Institutes of
Health, United States

Peter Kilmarx, an expert in global health and infectious disease research, policy, and programs, is the Deputy Director of the John E. Fogarty International Center of the National Institutes of Health, a preeminent center for global health research and capacity building.

He previously served as the Country Director in Zimbabwe and in Botswana for the U.S. Centers for Disease Control and Prevention (CDC) and as Chief of CDC's Sexual Transmission Research Section in Thailand.

Other CDC leadership positions included Senior Advisor to the Director for Health Reform and Chief of Epidemiology Branch, Division of HIV/AIDS Prevention. Dr. Kilmarx served for more than 20 years in the U.S. Public Health Service rising to the rank of Assistant Surgeon General (Rear Admiral). He played leadership roles in CDC's Ebola response efforts in Guinea, Sierra Leone, and Democratic Republic of Congo (DRC) and has published more than 150 peer-reviewed journal articles and book chapters.

His international career began as a Peace Corps volunteer in the DRC (then Zaire), where he helped develop fisheries that are still productive today.

No potential conflict of interest to report



International Conference Committee

Chewe Luo,
MD, PhD

UNICEF, United States /
University Teaching Hospital,
Zambia

Chewe Luo is a paediatrician and tropical health child specialist. She is the Chief of the HIV/AIDS Section and Associate Director in the Programme Division at the headquarters of UNICEF (United Nations International Children's Fund) in New York. Previously, she was the technical team leader for children and AIDS country programme scale-up and Senior Programme Advisor on HIV and Maternal Child Health for UNICEF.

Dr. Luo has over 20 years of experience in HIV and child health as both a clinician and a researcher at the University Teaching Hospital in Zambia, as a clinician in the United Kingdom, and in her work with UNICEF at country, regional, and headquarter levels.

Dr. Luo, a Zambian national, has a Masters of Medicine in Paediatrics from the University of Zambia, School of Medicine as well as a Masters in Tropical Paediatrics and a PhD from the Liverpool School of Tropical Medicine, Liverpool University, School of Medicine, in the United Kingdom.

Dr. Luo is a fellow of the Royal College of Physicians, Edinburgh, Scotland.

No potential conflict of interest to report



International
Conference Committee

Timothy Mastro,
MD, FACP, DTM&H

University of North Carolina
at Chapel Hill,
United States

Timothy Mastro is Chief Science Officer at FHI 360, Durham, North Carolina and Adjunct Professor of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dr. Mastro oversees FHI 360's research and science-based programs conducted in the United States and through FHI 360's offices in 60 countries around the world.

Dr. Mastro joined FHI 360 in 2008 following 20 years in scientific leadership positions at the US Centers for Disease Control and Prevention (CDC) in Atlanta. During 1993-2000, he served in Bangkok as Director of the CDC HIV/AIDS collaboration with the Thai Ministry of Public Health.

Dr. Mastro is author or co-author of more than 180 published articles and book chapters and has served on committees for the World Health Organization, UNAIDS, PEPFAR and the USA National Institutes of Health. Dr. Mastro trained in internal medicine at the Metropolitan Hospital and Mount Sinai School of Medicine, New York City. He studied at the London School of Hygiene and Tropical Medicine and received a DTM&H from the Royal College of Physicians of London.

Board-certified in internal medicine, he is a fellow of the American College of Physicians and member of the American Epidemiological Society.

No potential conflict of interest to report



Invited Speaker

Grace Mayanja

FHI 360,
Ethiopia

Grace Aheebwe Mayanja has more than 25 years of leadership of HIV/AIDS, OVC and child protection programs in multiple countries throughout sub-Saharan Africa. She is currently the Chief of Party (COP) for FHI 360's \$49 million PEPFAR/USAID-funded Caring for Vulnerable Children Activity in Ethiopia, where she is providing programmatic and technical oversight for the implementation of HIV prevention and comprehensive HIV services for vulnerable children and their families. With her leadership, the same program has spearheaded methodologies that have contributed to improved HIV outcomes for Children and Adolescents Living with HIV. The program has this year expanded OVC emergency programming into Tigray, Ethiopia, a region suffering armed conflict.

As COP on the PEPFAR/USAID-funded Strengthening Uganda's National Response for Implementation of Services for Orphans and Vulnerable Children (SUNRISE-OVC) project, Grace collaborated with the Government and strengthened social service systems that deliver improved HIV services for OVC.

She has 19 years of experience leading and supporting national institutional systems strengthening and capacity development of local implementing organizations implementing HIV services for children, adolescents, and youth.

She has OVC programs experience of PEPFAR and USAID, FHI 360, Care International, World Bank, Unicef, International HIV/AIDS Alliance, Cotton-on-Foundation and World Vision International.

No potential conflict of interest to report



International Conference Committee

**Nyaradzo Mavis
Mgodi,**
MBChB, MMed

University of Zimbabwe
Clinical Trials Research
Centre, Zimbabwe

Nyaradzo Mavis Mgodi, - JIAS Deputy Editor, Associate Editor at Frontiers in Global Reproductive Health - HIV and STIs - is a clinical pathologist with over 10 years of experience conducting clinical trials for HIV prevention in women of reproductive age in Sub-Saharan Africa, including Zimbabwe, home to the University of Zimbabwe-Clinical Trials Research Centre.

As lead investigator in Harare, she has overseen the implementation of several trials assessing acceptability, safety and effectiveness of oral PrEP, vaginal microbicides, the Dapivirine vaginal ring, long-acting injectable PrEP and broadly neutralizing antibodies for HIV prevention in African women at risk for HIV.

She is protocol co-chairperson for HVTN 703/HPTN 081 study, also known as Antibody Mediated Prevention (AMP) and of MTN 025/HOPE study. Nyaradzo, who serves as the International Principal Investigator on the HPTN Executive Committee, is also a scientific reviewer for the Medical Research Council of Zimbabwe, and has served as a technical advisor for the Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) survey. She is a member of the Policy and Implementation Steering Committee for the Global Evaluation of Microbicide Sensitivity (GEMS) project, HIVR4P Program Organizing Committee and served as Conference Advisory Committee member for International AIDS Society (IAS) 2017.

No potential conflict of interest to report



Local Organising Committee

Lisa Mills,
MD, MSc

Centers for Disease Control,
Uganda

Dr. Mills serves as the Associate Director for Science for CDC Uganda, overseeing the Surveys and Surveillance, Research and Evaluations undertaken by CDC Uganda and its partners. She first worked in Uganda 2004-2009 as a Johns Hopkins Infectious Diseases fellow focused on the initial roll-out of HIV treatment and the management and characterization of secondary infections in persons with advanced HIV.

Dr. Mills then began her CDC career in Kisumu, Kenya, as the site principal investigator for HIV Prevention Trials Network Study 052, the landmark HIV 'treatment as prevention' trial. From Kenya, she proceeded to Botswana as the CDC Director of the Botswana Combination Prevention Project, one of three PEPFAR-funded large community-randomized trials of combination HIV prevention to reduce community HIV incidence. She then served in CDC Rwanda before returning to Uganda in 2018 in her current role.

Dr. Mills completed her Residency in Internal Medicine at Massachusetts General Hospital and her Infectious Diseases Fellowship at the Johns Hopkins Medical Institutions. She received her MD from Cornell University and her Masters of Science in Clinical Investigation from Johns Hopkins School of Public Health through funding from the National Institutes of Health. She is board-certified in Internal Medicine and Infectious Diseases.

No potential conflict of interest to report



Invited Speaker

Penny Moore,
PhD

University of the
Witwatersrand and
National Institute for
Communicable Diseases,
South Africa

Penny Moore is the South African Research Chair of Virus-Host Dynamics and Research Professor at the University of the Witwatersrand and the National Institute for Communicable Diseases (NICD). She holds a joint appointment as CAPRISA Honorary Senior Scientist in Virus-Host Dynamics at the Centre for the AIDS Programme of Research (CAPRISA), University of Kwazulu-Natal and is Adjunct Member of the Institute of Infectious Disease and Molecular Medicine (IDM) at the University of Cape Town. She co-directs a team of more than 15 scientists and 10 postgraduate students who work in the field of HIV vaccine discovery, combining Virology and Immunology.

Her research is currently funded by the NIH, the SA Medical Research Council, the International AIDS Vaccine Initiative and the SA National Research Foundation. In the past 18 years that she has worked in the HIV field she has contributed towards more than 120 papers, focusing predominantly on HIV neutralizing antibodies and their interplay with the evolving virus, a result of extensive collaborations within South Africa and internationally. She has extensive experience with sequencing and analysis of HIV glycoproteins, measuring neutralizing antibodies antibody responses and the isolation and characterization of monoclonal antibodies to HIV antigens.

More recently, with the emergence of SARS-CoV-2, her team has redeployed many of these platforms and technologies, developing tools to measure humoral immune responses to SARS-CoV-2 infection and vaccination and also to isolate South African SARS-CoV-2-directed mAbs.

No potential conflict of interest to report



Invited Speaker

Sikhulile Moyo,
MSc, MPH, PhD

Botswana Harvard AIDS
Institute Partnership,
Botswana / Harvard T.H. Chan
School of Public Health,
United States

Medical Virologist based at the Botswana Harvard AIDS Institute Partnership (BHP). He is the laboratory director for the Botswana Harvard HIV Reference Laboratory and a Research Associate with the Harvard T.H. Chan School of Public Health. He is currently part of the presidential task team for COVID-19 as a co-chief scientist.

He has made several significant contributions in laboratory systems strengthening, the prevention of mother-to-child HIV transmission studies and studies that have informed birth outcomes, the health of HIV-exposed infants, surveillance of HIV incidence, and monitoring of HIV mutations associated with drug resistance. His research interests are focused on the characterization of acute and primary HIV-1 subtype C infection, HIV cure, molecular epidemiology of HIV-1C infection, viral evolution, design and evaluation of cross-sectional methods for estimating HIV incidence, including improved accuracy and incorporating analysis of HIV diversity and estimation of transmission time into multi-assay algorithms.

He is involved in various pathogen genomics studies including HIV, SARS-CoV-2, Hepatitis, Human Papillomavirus, TB, and Norovirus. He is currently mentoring several students. Recently Dr Moyo and his team contributed to the identification of the Omicron variant in Southern Africa. He has over 150 publications in peer-reviewed journals.

No Potential conflict of interest



Invited Speaker
Peter Mudiope, MD

Ministry of Health,
Uganda

Mudiope is a Medical Doctor with a Master's degree Epidemiology and Biostatistics from Makerere University, Kampala Uganda and Post Graduate Diploma in Project Planning and Management from Uganda Management Institute.

Currently Peter is the Coordinator HIV Prevention at the Ministry of Health Uganda, where he provides a 360-degree strategic stewardship in the area of HIV prevention. He has provided leadership in the developing and roll out of several key HIV Prevention policies, guidelines, and training materials. His current research interest are in the area of HIV and mental health with focus on implementation science research on adoption and roll out of models to optimize novel HIV prevention tools such as Medication assisted therapy; inject PrEP; event driven PrEP etc. He is the Principal Investigator on the WHO/UNAIDS funded BBS –LITE study, that is employing cost saving approaches to estimate SW & PWID size and profiles in Eastern Uganda.

From 2013 to 2016, Peter worked as Head of HIV Prevention at Uganda AIDS Commission for four years before joining the USAID funded project (RHITES-SW) as Director Clinical Services, where he was key in initiating and rolling out comprehensive Health and HIV/AIDS project in over 15 districts in South Western Uganda.

Peter has authored a number of publications won awards and research grants internationally such as the: The Women, Girls and HIV Investigator's award by the IAS and ICW & ICRW at the AIDS 2012 conference in Washington DC; The Young Investigator award, by the International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT Sep 2010: Awarded a Grant: Enhancing Family planning among HIV/AIDS mother in Mulago; Administrative Supplements for HIV/AIDS Implementation Science in PEPFAR Settings Notice Number: NOT-AI-10-023 (2010- 2012)

No potential conflict of interest to report



Invited Speaker
Victor Musiime, MBChB, MMed, PhD

Makerere University College
of Health Sciences,
Uganda

Victor Musiime is an Associate Professor at Makerere University, College of Health Sciences, School of Medicine, Department of Paediatrics and Child Health, in Kampala, Uganda. Here he provides didactic and clinical teaching to undergraduate and graduate students, conducts research, and supervises doctoral and masters research.

He also conducts research at Joint Clinical Research Centre (JCRC), where he holds the position of Senior Research Consultant. He has worked as a Paediatrician at JCRC in HIV research, clinical care and treatment since 2004. He has also been an investigator on several research protocols, including multicenter clinical trials, mainly in infectious diseases, and more particularly in Paediatric and Adolescent HIV/AIDS.

Victor also provides clinical care to children on the inpatient/outpatient wards of Mulago National Referral Hospital, the teaching hospital for Makerere University; particularly the Infectious diseases ward, the emergency ward, and the gastrointestinal outpatient clinic. In addition he sits on several local, regional and global advisory boards and technical working groups.

His clinical and research interests are in Infectious diseases, child nutrition, gastroenterology, and other child health issues.

Potential conflict of interest

ViiV and Viatrix



Local
Organising Committee
**Maria Sarah
Nabaggala,**
BStat, MSc
Infectious Diseases Institute,
Uganda

Ms is a senior statistician of Statistics and Data Management Unit, and research scientist at the Infectious Diseases Institute (IDI) at the Makerere University College of Health Sciences (MakCHS). She is the secretary of the International Biometric Society – Uganda region. She received her master's degree in Reproductive Health majoring in statistics from the School of Statistics, at Makerere University, Kampala.

As a Senior statistician, Maria Sarah focuses on providing technical guidance and support to ensure international comparability of data, adequate application of international statistical standards and data requirements from different stakeholders at the Infectious Diseases Institute. She has considerable experience in handling large and longitudinal datasets and has supported analyses using large local, regional and international HIV databases. She has also supported several clinical studies ranging from randomized clinical trials, observational studies and clinical diagnostics studies.

Maria Sarah has supported research through various research studies that have enabled her contribute to medical research findings body through publications thus contributing to the body of scientific evidence. As a researcher, her main areas of interest are in applied statistics, Public Health, implementation sciences and applied clinical research. Particularly, Maria Sarah has keen interest in HIV and reproductive related questions, polypharmacy and the HIV prevention, treatment and care monitoring cascade inclined research.

Potential conflict of interest

ViiV and Viatrix



Invited Speaker
Nanyeenya Nicholas,
MBChB, MPH
Ministry of Health CPHL,
Uganda

Dr. Nanyeenya Nicholas (MBChB, MPH) is an international laboratory systems strengthening consultant with a special focus in strengthening HIV viral load, early infant diagnosis (EID) and specimen referral programming across Africa, and has worked for the Global Fund projects in Sierra Leone and The Gambia, and for the ASLM LabCOP project in 11 African countries.

Nicholus is also a community health engagement specialist, engaging in various community awareness shows on various media platforms including TVs, radios, newspapers, social media, and community outreaches.

Currently, Nicholas works as a program officer at the Ministry of Health CPHL for HIV viral load, EID, COVID-19 and Sickle cell programs. He has research interests to end the HIV as an epidemic by 2030, and this is his motivation for his PhD at Makerere University School of Public Health where he is currently a doctoral researcher.

No potential conflict of interest to report



Invited Speaker

Laura Nyblade,
PhD

RTI International,
United States

Nyblade is a Fellow and Senior Technical Advisor on Stigma and Discrimination in the division for global health, RTI International. Previously, she was the Director of Stigma, Discrimination, and Gender at ICRW.

For the past twenty-five years, she has built and led a portfolio of research and programmatic work on HIV stigma with a focus on data utilization to support evidence-based program implementation and policy at local, national, and global levels. Most recently, with a focus on addressing HIV and intersecting stigmas in health facilities.

Working in close collaboration with civil society and governments across Africa, South and South-East Asia and the Caribbean, Dr. Nyblade has led the design, roll out and evaluation of evidence-based HIV stigma reduction programs, the development of programmatic tools to engage multiple audiences, and the development and validation of stigma measures. Building on the HIV stigma work,

Dr. Nyblade's current research and programmatic interests include exploring commonalities across disease stigmas that can be leveraged for a more efficient and effective response to multiple health stigmas.

No potential conflict of interest to report



Invited Speaker

Nickolas Paton,
MD, FRCP

National University of
Singapore, Singapore

Nicholas Paton trained in Medicine and Infectious Diseases in Cambridge, Sydney and London, and in Epidemiology at the London School of Hygiene and Tropical Medicine. From 1997 to 2005 he worked as Head of Department at the National HIV Referral Centre in Singapore and, in addition to clinical care responsibilities, developed a Centre for Research in HIV and Communicable Diseases. From 2006 to 2011 he worked at the UK MRC Clinical Trials Unit where he was the Chief Investigator of large HIV treatment trials such as PIVOT (a trial of a PI-monotherapy strategy done at 45 clinical sites in the UK); and EARNEST (testing options for second-line therapy in over 1200 patients in 5 countries in sub-Saharan Africa).

He currently holds a joint appointment as Professor of Infectious Diseases at the National University of Singapore and at the London School of Hygiene and Tropical Medicine. He is the Chief Investigator of the NADIA trial (comparing dolutegravir with darunavir and comparing maintenance of tenofovir versus switching to zidovudine in second-line therapy, done in 7 sites in Uganda, Kenya and Zimbabwe) and the scientific lead of the CARES trial (comparing long acting cabotegravir/rilpivirine with standard combination ART at 8 sites in Uganda, Kenya and South Africa).

In Singapore he leads a programme of TB trials focused on trials of host-directed therapies for TB and exploring novel TB trial outcome measures; and is the Chief Investigator on the TRUNCATE-TB trial (a strategy trial of 2 months of treatment for drug-susceptible TB done across a network of 18 sites in Asia and Africa).

Potential conflict of interest

ViiV and Viatrix



International Conference Committee

Sam Phiri,
DCM, MSc, PhD

Partners in Hope,
Malawi

Sam Phiri is a Programs Director at Partners in Hope (PIH) Malawi providing Strategic Leadership to a large PEPFAR/USAID supported HIV Care and Treatment Program managing over 197,000 PLHIV on ART. Before PIH, Dr Phiri was Executive Director of Lighthouse Trust in Malawi over 20 years managing PEPFAR/CDC Care and Treatment program with over 170,000 PLHIV on ART.

He is an accomplished implementation scientist with large body of published work in areas of PMTCT, ART, TB, and NCD integration. His interest is HIV Treatment and Care; Operational Research in Infectious Diseases particularly Sexually Transmitted Infections (STIs), HIV & AIDS and TB. Dr Phiri received a Masters Degree in Sexually Transmitted Infections and HIV from University of London - London School of Hygiene and Tropical Medicine and University College London, then awarded Doctoral of Philosophy Degree (PhD) in Clinical Epidemiology from University of London (LSHTM).

Dr Phiri is a Professor in Department of Medicine at University of North Carolina School of Medicine at Chapel Hill, USA; Department of Global Health at University of Washington in Seattle, USA and Faculty at Kamuzu College of Health Sciences, Lilongwe, Malawi.

No potential conflict of interest to report



Invited Speaker

Jürgen Rockstroh,
MD

HIV Outpatient Clinic,
University of Bonn,
Germany

Jürgen Rockstroh, is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. He earned a Doctor of Medicine degree from the Rheinische Friedrich-Wilhelms University of Bonn, and completed his residency in the Department of Medicine also at the University of Bonn. His department treats the world's largest cohort of HIV-infected hemophiliacs.

In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. More recently, he has also started working on the impact of COVID-19 on HIV-coinfection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV, hepatitis co-infection and COVID-19.

From 2007-2011 he was elected as the president of the German AIDS Society. He is also since 2009 a member of the executive committee of the European AIDS Clinical Society (EACS) and from 2011-2020 member of the governing council of the International AIDS Society. He also was the chair of the National German AIDS Advisory Panel from 2011-2017 and the EACS coinfection guidelines from 2008-2017. In 2015 Professor Rockstroh was elected chair of HIV in Europe (in 2019 renamed as EuroTEST) and from 2019-2020 president for EACS.

The German Society for Infectious Diseases awarded Dr Rockstroh and his co-authors the prize in clinical infectious diseases in 2002, and the national AIDS research prize in 2005. Dr Rockstroh has authored or co-authored over 700 publications in peer-reviewed journals, and over 100 book chapters.

Potential conflict of interest:

Abivax, Galapagos, Gilead, Janssen, MSD, NPO Petrovax Pharm LLC, Theratechnologies, and ViiV



Invited Speaker

Nadia Sam-Agudu,
MD, CTropMed

University of Maryland School
of Medicine / Institute of
Human Virology Nigeria,
United States / Nigeria

Nadia A. Sam-Agudu is a pediatrician working for the Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, USA, where she is also Associate Professor of Pediatrics in Immunology and Infectious Diseases. She is stationed full-time in Nigeria, where she serves as the Senior Technical Advisor for Pediatric and Adolescent HIV at the Institute of Human Virology Nigeria in Abuja.

Dr. Sam-Agudu graduated from the Mayo Clinic Medical School in 2002, and thereafter completed her training in Pediatrics and Pediatric Infectious Diseases at the University of Minnesota, USA. Her career focuses on the control and elimination of infectious diseases of public health importance among African children, specifically HIV, tuberculosis, and malaria.

Dr. Sam-Agudu has research experience in Ghana, Uganda and particularly in Nigeria, where she has provided technical and policy-making support for HIV programs since 2010. Her research interest is in using implementation science methods to generate evidence for sustainable HIV prevention and control among children and adolescents. To this end, she has to date served as Principal Investigator, Project Director or Mentor for projects supported by the World Health Organization, the US National Institutes of Health, the American Academy of Pediatrics, and the International AIDS Society.

No potential conflict of interest to report



Invited Speaker

Nelson Sewankambo,
MBChB, MSc, MMED, FRCP,
LLD (HC)

Makerere Medical School,
Uganda

Nelson Sewankambo is a Professor Emeritus and a former Dean of Makerere Medical School, Uganda and a past Principal Makerere University College of Health Sciences. He facilitated the establishment of many collaborations between Makerere University and institutions in both high and low or middle-income countries. He was a member of the research team that for the first time identified and documented the existence of HIV in Uganda in early 80's (Lancet, 1985).

He is one of the founders of the internationally renowned Rakai Health Sciences Program (RHSP), initially known as the Rakai Project which has a longitudinal population Rakai HIV Community Cohort Services (RCCS) for the last 35 years. RHSP has generated research evidence used in global (WHO), regional and national HIV prevention and management policies.

He is one of the founders of the world famous 20-year old Infectious Diseases Institute (IDI) at Makerere University. IDI has very strong HIV prevention, research, management and care programmes for the last 20 years. He was a founder and is a scientific adviser (20+ years) of the Makerere-University Walter Reed Research Institute (MUWRP) and a founding member and Board Chair of the Makerere Joint AIDS Program (MJAP) in Uganda.

He has focused on epidemiological and interventional HIV/AIDS research and also contributed to building indigenous research capacity to conduct quality research relevant to the country, region and globally.

No potential conflict of interest to report



Local
Organising Committee
Lillian Tatwebwa
Uganda AIDS Commission

Lilian Tatwebwa is the Head Special Programs at the Uganda AIDS Commission and has done tremendous work in coordinating regional HIV and AIDS program focusing on cross border and mobile populations with the aim of ensuring these population sub-groups access the much need HIV and AIDS services. She is key in coordinating the National Policy and Research agenda with a focus on promoting efforts to develop National HIV and AIDS Policies and Guidelines. She has contributed greatly to efforts in promoting HIV and AIDS related Research by coordinating International, regional and national HIV and AIDS conferences including efforts to find an HIV Vaccine. Lilian has also done a lot of work in mainstreaming gender in the HIV and AIDS program. She has been key in contributing to efforts to address HIV Stigma and Discrimination in the national HIV response.

No potential conflict of interest to report



Scientific Chair
Kwasi Torpey,
MD, PhD, MPH, FGCP,
FWACP
University of Ghana,
Ghana

Kwasi Torpey is a public health physician, HIV clinician, program manager, and researcher. Professor Torpey is an Associate Professor of Family Health and Head, Department of Population, Family, and Reproductive Health, College of Health Sciences, University of Ghana.

He has extensive experience in HIV program implementation in Ghana, Nigeria, Kenya, Uganda, Ethiopia, Eritrea, Tanzania, Mozambique, and Zambia. He has worked with USAID, CDC, DFID, World Bank, Global Fund, and other donors. He served as Deputy Chief of Party, Technical for the Strengthening Integrated Delivery of HIV/AIDS Services initiative of Family Health International (FHI) in Nigeria. He was a technical lead in designing and implementing Ghana's START program that introduced public sector antiretroviral treatment. He was Director of Technical Support in FHI's Zambia Prevention Care and Treatment Partnership.

He has published in international peer-reviewed scientific journals on HIV prevention, care, and treatment. In 2003, he was the first recipient of the Dr David Barry Memorial Award for Outstanding Contribution to AIDS Treatment Programs. He has a PhD from the Institute of Tropical Medicine, University of Antwerp, Belgium, an MPH from the Netherlands School of Public Health, and MD from the University of Ghana Medical School. He is a Fellow of Ghana's College of Physicians and Surgeons.

No potential conflict of interest to report



International
Conference Committee

François Venter,
MD, FCP, PhD

Ezintsha, University of the
Witwatersrand,
South Africa

WD François Venter, is the Head of Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training. His work involves health systems research that directly translates into national programmes, most recently involving the antiretrovirals dolutegravir and TAF.

He leads multiple antiretroviral treatment optimisation studies, and is currently working on new first and second line options, as well as patient linkage-to-care interventions and self-testing projects. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on men, women, children, young people, truckers, sex workers, and LGBTI communities. For over 20 years he has been an advisor to bodies such as the South African government, UNAIDS, and WHO, contributing to international, regional, and national HIV guidelines.

He is currently a member of the Department of Science and Technology's Research and Innovation Committee, advising on COVID-19 research and innovation needs. He has an active interest in medical ethics, and has been involved in several HIV-related human rights cases within the Southern African region.

He supervises a large number of Masters and PhD projects. Recent work has included publications in Lancet HIV, New England Journal of Medicine, Nature, AIDS, and PLOS Medicine.

Potential conflict of interest:

Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi, NIH, BMGF, Unitaid, SAMRC, and CIFF



Invited Speaker

Rhoda Wanyenze,
MBChB, MPH, PhD

Makerere University College
of Health Sciences,
Uganda

Rhoda Wanyenze, is a Professor and Dean at Makerere University School of Public Health. Prof. Wanyenze has vast experience in public health research, capacity building, and program management, especially in infectious diseases, sexual and reproductive health, and health systems.

She has wide experience in partnerships in Africa and currently leads an evaluation of the COVID-19 response across five countries and the Partnership to enhance technical support for analytical capacity and data use for HIV, TB and Malaria in 13 countries in Africa.

She has served on several Boards in Uganda and globally and is passionate about gender equity especially in Higher Education Institutions.

No Information



International
Conference Committee

**Stephen Watiti,
MD**

The Worldwide Hospice
Palliative Care Alliance
(WHPCA), Uganda

After studying Medicine at Makerere University, Kampala, Uganda, Dr. Watiti, MD was a medical officer, Rubaga Hospital, Kampala from 1985-1988. He practiced medicine privately from 1988-2004 at Entebbe Road clinic and JOY Medical Centre Ndeeba, Kampala. From 2004, he has been working at Mildmay Uganda, a leading HIV and AIDS service organisation. An HIV activist and ardent advocate for improved and sustainable health for all, Dr. Watiti believes with hindsight that he acquired HIV between 1985 and 1986 while working as a junior medical officer. In 2000, he began ARVs after contracting tuberculosis, cancer (Kaposi's sarcoma), and meningitis. In 2006, he started his weekly column on HIV in New Vision, Uganda's leading daily newspaper. His column appears Mondays under the heading: "Towards zero: with Doctor Watiti". He has published two books on HIV: "HIV and AIDS: 100 Commonly Asked Questions" and "Conquering HIV and AIDS: My personal experience of living with HIV".

The Tearfund UK has recognised him as an HIV Champion and he has won awards from Uganda's Parliament, Action Aid International, and International Christian Medical and Dental Association for his outstanding contribution towards the fight against HIV in Uganda and beyond. His current advocacy work focuses on HIV and aging.

No potential conflict of interest to report



Invited Speaker

**Nicola Willis,
MPhil**

Africaid, Zvandiri,
Zimbabwe

Nicola is the Executive Director of Zvandiri. She has spent 20 years living in Africa, initially in Ghana and South Africa, then Zimbabwe since 2004 when she established Zvandiri together with young people living with HIV and a group of volunteers in Harare.

Nicola is Co-Chair of the World Health Organisation's Technical Working Group for Adolescent HIV Service Delivery and is a member of WHO's HIV Guidelines Committee. In 2021, she was awarded a Rainer Arnhold Fellowship from The Mulago Foundation.

Nicola studied Paediatric Nursing at Nottingham University followed by Tropical Diseases Nursing at the London School of Hygiene and Tropical Medicine. She holds an MPhil in Public Mental Health from Stellenbosch University.

No potential conflict of interest to report



SUPPORT

GOLD LEVEL



VIATRIS

Mylan + Upjohn

Working together in HIV



National Institute of Allergy and Infectious Diseases, National Institutes of Health

BRONZE LEVEL



ENDORSERS



MEDIA PARTNER



LOCAL PARTNERS



[illegible]



What is the future of long - acting ARV injection therapies?

Wednesday, 12 May 2022 13:55-14:55

INTEREST Conference 2022

Kampala, Uganda

This educational session will explore:

- HIV Therapeutics Pipeline
- Virologic durability of long-acting injection therapies
- Describe the latest evidence underpinning the safety, efficacy and pharmacokinetics of long-acting treatment options for these conditions
- Describe the clinical management of HIV using long- acting ARV injections
- Treatment emergent resistance

SYMPOSIUM INVITATION

Date: Thursday, 12th May 2022

Time: 09:25 – 10:25 GMT +3

Topic: Real world experience of paediatric HIV management “An African perspective”



Trademarks are owned by or licensed to the GSK group of companies or its licensor.

Please report adverse events with any GSK/ViiV Healthcare products at mu.zinchub@gsk.com

If you have any comments or questions, please contact us on: sibongile.s.kubheka@viiivhealthcare.com

Date of preparation: April 2022 - NX-ZA-HVX-AGND-220001



*Gilead is a proud
GOLD SPONSOR
of **INTEREST 2022***

*Kampala, Uganda:
10 – 13 May 2022*

Creating Possible

For more than 30 years, Gilead has created breakthroughs once thought impossible for people living with life-threatening diseases. We are a leading biopharmaceutical company with a pioneering portfolio and ever-expanding pipeline of investigational medicines.

Our commitment goes well beyond science. We innovate with the goal of eliminating barriers and providing access to healthcare for people who need it most. We are committed to a better, healthier world for everyone.



interestconference.org